We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 3, 2005
Last Update Posted: July 4, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Transport Pharmaceuticals
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating. Iontophoresis uses electric current to enhance the delivery of drugs through the skin. This trial is testing a new iontophoretic device for the delivery of acyclovir cream to treat cold sores.

Condition Intervention Phase
Herpes Labialis Device: iontophoretic acyclovir Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontophoretic Application of Acyclovir 5% Cream With an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Treatment of Recurrent Herpes Labialis

Resource links provided by NLM:

Further study details as provided by Transport Pharmaceuticals:

Primary Outcome Measures:
  • Clinician assessed duration of the herpetic episode measured from time of treatment until lesion healed. Lesion assessments for a minimum of 5 consecutive days and a maximum of 10 consecutive days.

Secondary Outcome Measures:
  • Clinician assessed prevention of progression to a classical lesion
  • Clinician assessed duration of classical herpetic lesions.
  • Clinician assessed duration of the herpetic lesion (aborted lesions will be assigned a duration of lesion value of 0 for the purposes of the statistical analysis).
  • Clinician assessed duration of the herpetic lesion hard scab.
  • Examine the safety of iontophoretic application of acyclovir 5% cream.
  • All assessments for a minimum of 5 consecutive days and a maximum of 10 consecutive days.

Estimated Enrollment: 1800
Study Start Date: April 2005
Estimated Study Completion Date: December 2005
Detailed Description:
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iontophoretically-applied acyclovir 5% cream for the treatment of herpes simplex labialis lesions including an open label arm using Zovirax (acyclovir) Cream 5% as per standard of care in the same patient population. Subjects who meet the eligibility requirements at the screening/randomization visit will be randomized in a 1:1:1 ratio to one of the three treatment groups. After being enrolled and randomized into the study, subjects will be sent home with a locked kit containing the iontophoretic device with either active or placebo cream or a locked kit containing Zovirax Cream 5%. At first signs and/or symptoms of a recurrent herpetic episode (Stage 0 or 1, prodromal or erythema), the lesion will be confirmed by telephone interview with the subject, and upon confirmation of the lesion, the subject will be given the combination to the locked kit and instructed to begin treatment immediately, thereby initiating the Treatment Phase of the study. Subjects will be followed for at least 5 consecutive days post-treatment up until a maximum of 10 consecutive days post-treatment, until the herpes lesion is healed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male or female subject 18-75 years of age
  2. Female subject must be using a medically acceptable form of birth control during the study. Acceptable birth control measures are abstinence, oral contraceptive pills or patch, injectable contraception, barrier contraceptives (condom, diaphragm with spermicide), IUD, surgical (hysterectomy, tubal ligation), vasectomized partner, or natural post menopausal inability to conceive.
  3. Subject must have a history of recurrent herpes labialis and report at least 3 recurrences during the preceding 12 months.
  4. Subject must provide voluntary written informed consent to participate in this study.

Exclusion Criteria:

  1. Subjects with a pacemaker, or a history of cardiac arrhythmias or conduction abnormalities. Any subject with a medically confirmed history of cardiac arrhythmia including sinus arrhythmia, premature beat, heart block, atrial fibrillation, atrial flutter and pulsus alternans is to be excluded from the study.
  2. Any evidence of active malignancy, immunodeficient disease, or use of immunomodifying drugs (e.g., systemic steroids) within 30 days prior to enrollment. Subjects who have completed therapy and are considered unlikely to relapse or who have had surgery and do not have any evidence of disease, are eligible for the study.
  3. Subjects using topical steroids on or near the face or systemic (oral, intravenous) steroids within 30 days of enrollment; use of inhaled steroids does not exclude a subject from the study.
  4. History of allergic or adverse response to acyclovir, or any related anti-viral drug, or the cream base.
  5. In females of childbearing potential, a positive urine pregnancy test at time of screening.
  6. Subject is considered unreliable or unable to understand or follow the protocol directions or is unable to comprehend or satisfactorily use the measurement scales as determined by investigator or designee at screening.
  7. Subject has abnormal skin conditions that occur in the area ordinarily affected by cold sores which might affect the normal course of cold sores (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders).
  8. Subject is currently enrolled in another clinical trial or has used an investigational drug/device within 30 days of enrollment.
  9. Subject has previously participated in the current study (TPI-203).
  10. Subject has used an anti-viral medication in the preceding 30 days.
  11. Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs). If a subject is unlikely to get through the treatment phase of the protocol without requiring the use of analgesia for a chronic condition, e.g. back pain, recurrent daily headaches, the subject should be excluded.
  12. Subject has a recent history of renal dysfunction or serious hepatic disease. Renal dysfunction encompasses both acute and chronic renal failure, the former resulting from the sudden loss of the ability of the kidneys to excrete wastes, concentrate urine, and conserve electrolytes and the latter the gradual and progressive loss of these capabilities. Examples of serious hepatic disease would include alcoholic liver disease, chronic hepatitis, autoimmune hepatitis and a variety of inherited diseases. The underlying cause of a documented recent mild increase in liver enzymes should be considered when deciding whether or not to exclude such a subject.
  13. Subject has a history of alcoholism or drug abuse within the preceding 12 months. A subject with a history of a pathological pattern of alcohol use that causes a serious impairment of social or occupational functioning should be excluded. Such subjects may exhibit symptoms of tolerance and withdrawal along with other behavioral symptoms.
  14. Subject is institutionalized.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230867

  Hide Study Locations
United States, Alabama
Radiant Research Birmingham
Birmingham, Alabama, United States, 35209
United States, Arizona
Radiant Research Phoenix Southeast
Chandler, Arizona, United States, 85225
Radiant Research Phoenix
Phoenix, Arizona, United States, 85013
Radiant Research Scottsdale
Scottsdale, Arizona, United States, 85251
United States, California
Radiant Research San Diego
San Diego, California, United States, 92123
Radiant Research Santa Rosa
Santa Rosa, California, United States, 95405
United States, Florida
Radiant Research St. Petersburg
Pinellas Park, Florida, United States, 33781
Radiant Research Stuart
Stuart, Florida, United States, 34996
Radiant Research West Palm
West Palm Beach, Florida, United States, 33407
United States, Georgia
Radiant Research Atlanta West
Atlanta, Georgia, United States, 30308
Radiant Research Atlanta
Atlanta, Georgia, United States, 30342
United States, Idaho
Radiant Research Boise
Boise, Idaho, United States, 83704
United States, Illinois
Radiant Research Chicago
Chicago, Illinois, United States, 60610
United States, Minnesota
Radiant Research Minneapolis
Edina, Minnesota, United States, 55435
United States, Missouri
Radiant Research St. Louis
St. Louis, Missouri, United States, 63141
United States, New York
Rochester Clinical Research, Inc.
Rochester, New York, United States, 14609
United States, Ohio
Radiant Research Cincinnati
Cincinnati, Ohio, United States, 45236
Pediatric Clinical Trials International
Columbus, Ohio, United States, 43205
United States, Pennsylvania
Radiant Research Philadelphia
Philadelphia, Pennsylvania, United States, 19115
United States, South Carolina
Radiant Research Greer
Greer, South Carolina, United States, 29651
United States, Texas
J & S Studies, Inc.
Bryan, Texas, United States, 77802
Radiant Research Dallas North
Dallas, Texas, United States, 75231
Radiant Research San Antonio
San Antonio, Texas, United States, 78229
United States, Utah
Univeristy of Utah Health Sciences
Salt Lake City, Utah, United States, 84132
United States, Washington
Dermatology & Laser Center NW
Bellingham, Washington, United States, 98225
Radiant Research Tacoma
Lakewood, Washington, United States, 98499
Sponsors and Collaborators
Transport Pharmaceuticals
Principal Investigator: Christopher M Hull, MD University of Utah
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00230867     History of Changes
Other Study ID Numbers: TPI-203
First Submitted: September 29, 2005
First Posted: October 3, 2005
Last Update Posted: July 4, 2006
Last Verified: June 2006

Keywords provided by Transport Pharmaceuticals:
herpes labialis
cold sore

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents